At a glance
| Peptide length | 32 amino acids |
|---|---|
| Action | Osteoclast inhibition |
| Injectable roles | Hypercalcemia and selected bone disorders |
| Osteoporosis limitation | Alternatives must be unsuitable |
| Key long-term concern | Possible increased malignancy risk |
Overview
The salmon sequence is used pharmacologically because it has substantial activity at human calcitonin receptors. Injectable calcitonin can lower high blood calcium quickly and inhibit excessive bone resorption in Paget disease. US osteoporosis labeling reserves treatment for people for whom alternatives are unsuitable. Nasal and injectable products have different indications and absorption, so the route must be identified when describing evidence. Calcitonin is an older peptide medicine whose current clinical role is narrower than broad bone-health marketing suggests. European regulators restricted its long-term use after reviewing cancer findings; regulatory recommendations therefore need to be stated by jurisdiction.
How it works
Calcitonin activates receptors on osteoclasts and reduces their bone-resorbing activity. It also changes renal calcium handling, helping lower circulating calcium. These actions make it an antiresorptive calcium-regulating drug, unlike PTH analogs that can stimulate new bone formation with intermittent exposure. Receptor adaptation and antibody formation can diminish response, so an initial biochemical effect does not guarantee durable control of the underlying disease.
Approved uses depend on formulation
The injectable label covers symptomatic moderate-to-severe Paget disease when alternatives are unsuitable, early treatment of hypercalcemic emergencies with other appropriate care, and osteoporosis more than five years after menopause when alternatives are unsuitable. Lowering calcium temporarily does not treat the cancer, endocrine condition, or other disease causing hypercalcemia.
Supporting sources [1]
What is established for osteoporosis?
The current injectable label states that fracture-reduction efficacy has not been demonstrated. This qualification should remain visible even though some historical nasal-spray trials reported vertebral-fracture findings. European review concluded that the long-term osteoporosis benefit did not justify the identified cancer risk and recommended withdrawal of the nasal osteoporosis indication.
Important safety considerations
Serious allergic reactions, including anaphylaxis, can occur. Excessive calcium lowering may cause muscle spasms or seizures. Long-term studies of nasal and investigational oral formulations found more malignancies than placebo; the injectable label does not exclude a similar risk with prolonged systemic use. Response can also fall as antibodies develop.
Supporting sources [1]
Is nasal calcitonin interchangeable with injections?
No. Formulations differ in approved conditions, exposure, and practical use. An osteoporosis nasal product should not be represented as emergency treatment for severe hypercalcemia. For every route, the intended duration and continuing need require reassessment because the balance of benefit and risk changes with the condition being treated.
Reading this profile
Jurisdiction: United States; indications and availability vary by formulation and country.. Molecular class: Synthetic 32-amino-acid calcitonin peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Calcitonin-salmon injection — US prescribing information ↗Regulatory source · Checked 2026-10-27
- EMA calcitonin referral and restrictions ↗Regulatory source · Checked 2026-10-27